These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 29602288)
1. Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy. Shoeibi A; Olfati N; Litvan I Expert Opin Investig Drugs; 2018 Apr; 27(4):349-361. PubMed ID: 29602288 [TBL] [Abstract][Full Text] [Related]
2. Investigational therapeutics for the treatment of progressive supranuclear palsy. Coughlin DG; Litvan I Expert Opin Investig Drugs; 2022 Aug; 31(8):813-823. PubMed ID: 35695010 [TBL] [Abstract][Full Text] [Related]
3. The diagnosis of progressive supranuclear palsy: current opinions and challenges. Ali F; Josephs K Expert Rev Neurother; 2018 Jul; 18(7):603-616. PubMed ID: 29902389 [TBL] [Abstract][Full Text] [Related]
5. A Review of Treatment Options for Progressive Supranuclear Palsy. Stamelou M; Höglinger G CNS Drugs; 2016 Jul; 30(7):629-36. PubMed ID: 27222018 [TBL] [Abstract][Full Text] [Related]
6. How can we manage progressive supranuclear palsy syndrome with pharmacotherapy? Lozupone M; Dibello V; Daniele A; Solfrizzi V; Resta E; Panza F Expert Opin Pharmacother; 2024 Apr; 25(5):571-584. PubMed ID: 38653731 [TBL] [Abstract][Full Text] [Related]
7. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Boxer AL; Yu JT; Golbe LI; Litvan I; Lang AE; Höglinger GU Lancet Neurol; 2017 Jul; 16(7):552-563. PubMed ID: 28653647 [TBL] [Abstract][Full Text] [Related]
8. Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease. Anand K; Sabbagh M Expert Opin Investig Drugs; 2015; 24(10):1355-60. PubMed ID: 26289787 [TBL] [Abstract][Full Text] [Related]